The Malaysia Insulin Infusion Pump Market size is estimated at USD 0.81 million in 2024, and is expected to reach USD 0.92 million by 2029, growing at a CAGR of 2.60% during the forecast period (2024-2029).
According to the Agency for Clinical Research (ICR), a research agency affiliated with the National Institutes of Health (NIH), seven out of ten patients who died from COVID-19 in Malaysia had diabetes. The NHMS also discovered that around 8.1% of Malaysia's adult population, or 1.7 million people, have all three risk factors for diabetes, hypertension, and high cholesterol, the three major noncommunicable illnesses. Diabetes, according to STAT, is characterized by a chronic inflammatory condition that may result in a greater response to COVID-19 or an immunological overreaction that may cause organ damage. Diabetes can also compromise the immune system, and people with type-2 diabetes have more ACE2 receptors in numerous organs, making them more vulnerable to COVID-19 invasion.
Regarding diabetes gadgets, the monitoring category has a substantial market share. Over 100 million individuals worldwide need insulin, including all Type-1 diabetics and 10% to 25% of Type-2 diabetics, who are all required to regularly monitor their glucose levels. Insulin production is exceedingly complex, with just a few manufacturers on the market. As a result, there is fierce competition among these businesses, which always strive to match patient demands by providing the highest-quality insulin.
According to the National Diabetes Registry (NDR) of the Ministry of Health, 84% of diabetes patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension topping the list and driving the market throughout the forecast period.
The government is collaborating with the private sector to develop a program to train healthcare staff and, eventually, carers. Malaysia has the highest diabetes incidence in the Western Pacific and one of the highest in the world, with an annual cost of more than 600 million US dollars. Several variables, including population increase, aging, urbanization, and growing obesity and physical inactivity, contribute to the emerging trend. The growing prevalence of diabetes and its effects in Malaysia motivated this study to comprehensively identify, define, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Insulin therapy is the most effective hypoglycemic drug for diabetes treatment; nonetheless, insulin strength deteriorates when inadequately managed. NCDs, including diabetes, are responsible for more than 70% of all fatalities in Malaysia.
The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, characterize, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Although the use of insulin pumps has expanded dramatically in the West, particularly among type 1 diabetics, it is still quite restricted in Malaysia. The basal insulin infusion, which replaces intermediate- or long-acting subcutaneous insulin injections, delivers insulin continuously throughout the day at predetermined rates adjusted based on the individual's needs.
Owing to the above factors, the market will likely continue to grow.
According to the National Health and Nutrition Survey, one in every two Malaysian people is overweight or obese. Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient insulin utilization, known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity influence this process.
The government is working with the commercial sector on a program to train healthcare personnel and, eventually, carers. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes. It is also working with the private sector on a training program.
As a result, Malaysia's Insulin Pump Devices market is predicted to expand gradually in the coming years.
This product will be delivered within 2 business days.
According to the Agency for Clinical Research (ICR), a research agency affiliated with the National Institutes of Health (NIH), seven out of ten patients who died from COVID-19 in Malaysia had diabetes. The NHMS also discovered that around 8.1% of Malaysia's adult population, or 1.7 million people, have all three risk factors for diabetes, hypertension, and high cholesterol, the three major noncommunicable illnesses. Diabetes, according to STAT, is characterized by a chronic inflammatory condition that may result in a greater response to COVID-19 or an immunological overreaction that may cause organ damage. Diabetes can also compromise the immune system, and people with type-2 diabetes have more ACE2 receptors in numerous organs, making them more vulnerable to COVID-19 invasion.
Regarding diabetes gadgets, the monitoring category has a substantial market share. Over 100 million individuals worldwide need insulin, including all Type-1 diabetics and 10% to 25% of Type-2 diabetics, who are all required to regularly monitor their glucose levels. Insulin production is exceedingly complex, with just a few manufacturers on the market. As a result, there is fierce competition among these businesses, which always strive to match patient demands by providing the highest-quality insulin.
According to the National Diabetes Registry (NDR) of the Ministry of Health, 84% of diabetes patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension topping the list and driving the market throughout the forecast period.
Malaysia Insulin Infusion Pump Market Trends
Insulin Pump is Expected to Witness Growth Over the Forecast Period
An insulin pump is a device that continuously or, as needed, distributes insulin. The pump is modeled after the human pancreas. The insulin infusion pump can be used instead of a daily injection regimen or an insulin pen. Insulin pump treatment is a popular technique of insulin delivery for people with type 1 diabetes (T1DM). Pumps are a well-known and tried-and-true therapeutic option for T1DM patients of all ages, providing near-physiological insulin administration when the pancreas fails to generate insulin. Remote-controlled insulin pumps allow parents to suspend or bolus insulin from a safe distance while their child is playing or eating.The government is collaborating with the private sector to develop a program to train healthcare staff and, eventually, carers. Malaysia has the highest diabetes incidence in the Western Pacific and one of the highest in the world, with an annual cost of more than 600 million US dollars. Several variables, including population increase, aging, urbanization, and growing obesity and physical inactivity, contribute to the emerging trend. The growing prevalence of diabetes and its effects in Malaysia motivated this study to comprehensively identify, define, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Insulin therapy is the most effective hypoglycemic drug for diabetes treatment; nonetheless, insulin strength deteriorates when inadequately managed. NCDs, including diabetes, are responsible for more than 70% of all fatalities in Malaysia.
The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, characterize, and quantify Malaysia's pooled prevalence of diabetes and prediabetes. Although the use of insulin pumps has expanded dramatically in the West, particularly among type 1 diabetics, it is still quite restricted in Malaysia. The basal insulin infusion, which replaces intermediate- or long-acting subcutaneous insulin injections, delivers insulin continuously throughout the day at predetermined rates adjusted based on the individual's needs.
Owing to the above factors, the market will likely continue to grow.
Rising diabetes prevalence in the country is anticipated to boost the market studied
Diabetes and prediabetes are rising in Malaysia; thus, the government is implementing diabetes prevention and control campaigns nationwide. The Malaysian government should take a comprehensive approach and plan to enhance diabetes awareness, control, prevention, and treatment to minimize the incidence of diabetes in the country. Overweight and obesity contribute significantly to Malaysia's younger diabetic population.According to the National Health and Nutrition Survey, one in every two Malaysian people is overweight or obese. Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient insulin utilization, known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity influence this process.
The government is working with the commercial sector on a program to train healthcare personnel and, eventually, carers. The government is currently investigating the Sama-Sama project, which aims to empower family members and carers to help individuals living with diabetes to enhance disease control and outcomes. It is also working with the private sector on a training program.
As a result, Malaysia's Insulin Pump Devices market is predicted to expand gradually in the coming years.
Malaysia Insulin Infusion Pump Industry Overview
Due to the existence of only a few big businesses operating internationally and locally, the insulin infusion pump industry is concentrated. The competitive landscape includes examining a few well-known worldwide and local organizations, such as Medtronic PLC, Insulet Corporation, Ypsomed, Ascensia Diabetes Care, and Tandem Diabetes Care.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION
6 MARKET INDICATORS
7 COMPETITIVE LANDSCAPE
Methodology
LOADING...
